OmniAb, Inc. is a biotechnology company focused on accelerating the discovery and development of therapeutic antibodies. The company’s core business revolves around proprietary in vivo and in vitro platforms that generate fully human or humanized antibodies with high affinities and diverse epitope coverage. By offering integrated services spanning target validation, lead generation, and optimization, OmniAb partners with pharmaceutical and biotechnology firms to advance antibody drug candidates against a range of disease targets.
Central to OmniAb’s offering are its proprietary animal-based platforms, including genetically engineered rats, chickens, and other species designed to produce human antibody repertoires. These platforms are complemented by advanced screening and sequencing technologies that enable rapid identification of candidate molecules. In addition to its in vivo capabilities, OmniAb provides antibody engineering services—such as affinity maturation, isotype switching, and Fc engineering—to tailor biophysical and pharmacokinetic properties for preclinical and clinical development.
Founded in the late 2010s by a team of immunology and drug discovery experts, OmniAb went public on the Nasdaq under the ticker OABI in 2021 via a special purpose acquisition company. Since then, the firm has established research facilities in North America and Europe and forged collaborations with leading global biopharma organizations. These partnerships leverage OmniAb’s platforms to address oncology, immunology, infectious diseases, and rare disorders, underscoring the company’s role in generating next-generation antibody therapeutics.
OmniAb’s management team is composed of seasoned professionals with extensive experience in antibody discovery, biomanufacturing, and strategic alliances. Guided by a board of directors with deep scientific and commercial expertise, the company continues to enhance its technology suite and expand its collaborative network, positioning itself as a key provider of antibody discovery solutions in the global life sciences industry.
AI Generated. May Contain Errors.
